Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS-CoV-2 in dialysis patients.

Emre YasarYesim YildizErensu OzturkEbru Gok OguzEzgi Coskun YenigunRamazan OzturkOzant HelvaciHasan Selçuk ÖzgerMeryem KelesCengiz KaracinAsiye Ugras DikmenKayhan CaglarMurat DuranayMehmet Deniz AyliMurat DizbayYasemin ErtenGalip GuzUlver Derici

Published in: Nephrology (Carlton, Vic.) (2024)

Our results may indicate the need for additional vaccination doses in patients with HD and PD. Our findings indicate a higher antibody response in dialysis patients with heterologous BNT162b2 as a booster dose after two doses of CoronaVac compared to homologous CoronaVac.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
sars cov
dna damage
dna repair
newly diagnosed
ejection fraction
prognostic factors
randomized controlled trial
study protocol
patient reported outcomes
binding protein
patient reported